Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies for Multiple Myeloma — What Clinicians Want To Know

A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

Program Schedule — Central Time
Friday, December 11, 2026
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Location
Sheraton New Orleans Hotel
500 Canal Street
New Orleans, Louisiana
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

No registration fee is charged for this event. Preregistration is required for in-person attendance in New Orleans as seating is limited.

Adam D Cohen

Faculty

Adam D Cohen

MD

Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

Professor of Medicine (Hematology-Oncology), Director, Myeloma Immunotherapy, Co-Director, Amyloidosis Program

Meletios-Athanasios (Thanos) C Dimopoulos

Faculty

Meletios-Athanasios (Thanos) C Dimopoulos

MD

National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece

Professor and Chairman, Plasma Cell Dyscrasias Unit, Section of Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine

Suzanne Trudel

Faculty

Suzanne Trudel

MD

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Consultant

University of Toronto, Ontario, Canada

Bloom-Reece Professorship in Multiple Myeloma, Professor of Medicine

Ontario Cancer Institute, Toronto, Ontario, Canada

Clinician Scientist

Natalie S Callander

Moderator

Natalie S Callander

MD

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

This activity is supported by educational grants from Genentech, a member of the Roche Group, and GSK.

Join us on Friday, December 11th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).

Topics to Be Discussed

  • Current Utility of Antibody-Drug Conjugates (ADCs) for Multiple Myeloma (MM)
  • Ocular Toxicities and Other Tolerability Considerations with ADCs for MM
  • Integrating BCMA-Targeted Bispecific Antibodies into the Management of MM: Efficacy, Safety and Adverse-Event Management

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Assess available clinical research findings with BCMA-directed antibody-drug conjugates (ADCs) for MM to facilitate their integration into management algorithms.
  • Develop strategies to identify patients appropriate for treatment with BCMA-directed ADC therapy, and counsel them regarding the risks and benefits.
  • Implement a plan of care to recognize and manage the toxicities associated with bispecific antibodies and ADCs commonly used for MM in order to maintain patient quality of life and time on treatment.
  • Assess available research data with BCMA-directed bispecific antibodies for patients with relapsed/refractory (R/R) MM, and appreciate the clinical role of these agents.
  • Recall recently presented clinical trial results establishing the definitive efficacy of BCMA-directed bispecific antibody therapy in combination with anti-CD38 monoclonal antibody therapy for patients with R/R MM, and integrate this novel therapeutic strategy into management algorithms.
  • Recall available data with novel bispecific antibody- and ADC-based strategies currently under investigation for MM, and as applicable, discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Prof Dimopoulos — Advisory Committees and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma, Takeda Pharmaceutical Company Limited. Dr Trudel — Advisory Committees: AstraZeneca Pharmaceuticals LP, GSK, Janssen Biotech Inc, Kite, A Gilead Company, Opna Bio, Pfizer Inc, Sanofi; Consulting Agreements: GSK; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, K36 Therapeutics, Pfizer Inc, Roche Laboratories Inc. Additional faculty to be announced.

MODERATOR
Dr Callander has no relevant financial relationships to disclose. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, and GSK.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

Register for webcast

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Relapsed/Refractory Multiple Myeloma

Accreditation types: 1.5 NCPD

Expires: July 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Beth Faiman

Faculty

Beth Faiman

PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Adult Nurse Practitioner, Department of Hematology and Medical Oncology

Case Comprehensive Cancer Center, Cleveland, Ohio

Member, Population and Cancer Prevention Program

Hans Lee

Faculty

Hans Lee

MD

Sarah Cannon Research Institute, Nashville, Tennessee

Director, Multiple Myeloma Research

Mary Steinbach

Nurse

Mary Steinbach

PhD-c, DNP, FNP-C, APRN

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

Lead Ambulatory Advanced Practice Clinician, Division of Hematology

Natalie S Callander

Moderator

Natalie S Callander

MD

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma (MM).

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with MM.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for relapsed/refractory (R/R) MM in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

  • Consider published research findings and other clinical factors that affect the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with R/R MM.
  • Evaluate the biological rationale for chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and discuss with patients when and if this novel strategy should be considered.
  • Educate patients with R/R MM about the mechanism of action of, available and emerging data with and current clinical role of BCMA- and non-BCMA-directed bispecific antibodies.
  • Review recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for R/R MM, and recognize the current clinical role of this form of treatment.
  • Appreciate the mechanism of action of, unique characteristics of and available and emerging data with the various cereblon E3 ligase modulators under development, to prepare for their potential clinical availability for patients with R/R MM.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used, recently approved and promising emerging systemic therapies for MM.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 17, 2026, to July 17, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/RRMultipleMyeloma/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Faiman is on advisory committees and has consulting agreements with Janssen Biotech Inc and Sanofi. 

Dr Lee has consulting agreements (paid to institution) with AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, and Takeda Pharmaceuticals USA Inc; has consulting agreements (paid to self) with Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, and Takeda Pharmaceuticals USA Inc; has contracted research with AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc; and is on data and safety monitoring boards/committees for Allogene Therapeutics and Takeda Pharmaceuticals USA Inc. 

Ms Steinbach is on advisory committees with Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc, and Regeneron Pharmaceuticals Inc; has contracted research with and is on speakers bureaus for Johnson & Johnson, Pfizer Inc, and Regeneron Pharmaceuticals Inc.

All of the relevant financial relationships above have been mitigated.

MODERATOR
Dr Callander has no relevant financial relationships to disclose.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

Release date: July 17, 2026
Expiration date: July 17, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

  • for-nurses

Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Relapsed/Refractory Multiple Myeloma

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

Location

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room

Grand Ballroom A-F (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Faculty

Beth Faiman

Faculty

Beth Faiman

PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Adult Nurse Practitioner, Department of Hematology and Medical Oncology

Case Comprehensive Cancer Center, Cleveland, Ohio

Member, Population and Cancer Prevention Program

Hans Lee

Faculty

Hans Lee

MD

Sarah Cannon Research Institute, Nashville, Tennessee

Director, Multiple Myeloma Research

Mary Steinbach

Faculty

Mary Steinbach

PhD-c, DNP, FNP-C, APRN

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

Lead Ambulatory Advanced Practice Clinician, Division of Hematology

Natalie S Callander

Moderator

Natalie S Callander

MD

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

Meeting space has been assigned to provide a symposium supported by Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

    Program Schedule — Central Time

    11:45 AM – 12:15 PM — Registration and Lunch
    12:15 PM – 1:45 PM — Educational Meeting

    MODULE 1: Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

    • Rationale for targeting B-cell maturation antigen (BCMA) with CAR T-cell therapy for MM
    • Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for heavily pretreated MM
    • Available data with and FDA approvals of ide-cel and cilta-cel in earlier settings; overall survival (OS) advantage documented with cilta-cel
    • Identification of appropriate candidates for BCMA-targeted CAR T-cell therapy and optimal sequencing of this strategy opposite other evidence-based approaches
    • Early data with and ongoing evaluation of CAR T-cell platforms with targets beyond BCMA (eg, the GPRC5D-directed agent arlocabtagene autoleucel)

    MODULE 2: Tolerability and Other Practical Considerations with CAR T-Cell Therapy

    • Overview of the CAR T-cell manufacturing and delivery processes
    • Incidence, timing and signs and symptoms of cytokine release syndrome (CRS), neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) and other acute adverse events (AEs) with CAR T-cell therapy; optimal patient monitoring after infusion
    • Guideline-endorsed approaches for mitigation and management of CRS, neurotoxicity/ICANS and other AEs with CAR T-cell therapy; role of corticosteroids, tocilizumab and other supportive care interventions
    • Educating patients about practical requirements after CAR T-cell infusion (eg, the need to remain within proximity of the treatment center, recommendations regarding driving); implications of the recent elimination of the Risk Evaluation and Mitigation Strategy program for CAR T-cell therapy
    • Potential for long-term tolerability/toxicity concerns (eg, delayed neurotoxicity, prolonged cytopenias, hypogammaglobulinemia, infections, secondary malignancies) with CAR T-cell therapy

    MODULE 3: Role of B-Cell Maturation Antigen (BCMA)- and Non-BCMA-Targeted Bispecific Antibodies for MM

    • Mechanistic similarities and differences between bispecific antibodies and CAR T-cell therapy; targets of various approved bispecific antibodies (eg, teclistamab, elranatamab, linvoseltamab, talquetamab)
    • Long-term outcomes observed in pivotal trials of the BCMA-targeted bispecific antibodies teclistamab and elranatamab for heavily pretreated MM
    • Efficacy and safety data leading to the FDA approval of the anti-BCMA bispecific antibody linvoseltamab for R/R MM
    • Available efficacy and safety data with the non-BCMA-targeted bispecific antibody talquetamab for heavily pretreated disease
    • Optimal selection of candidates with R/R MM for BCMA- and non-BCMA-targeted bispecific antibodies; considerations guiding the sequencing of these agents relative to other strategies and each other

    MODULE 4: Toxicities and Practical Issues Related to Bispecific Antibodies

    • Potential practical advantages of the “off-the-shelf” nature of bispecific antibodies
    • Routes of administration, recommended dosing schedules and premedications with the various bispecific antibody platforms for MM; duration of hospitalization during step-up dosing
    • Comparative tolerability of BCMA- and non-BCMA-directed bispecific antibodies for MM
    • Incidence, severity and time course of CRS and neurotoxicity with bispecific antibodies; recommended protocols for mitigation and management
    • Spectrum, frequency and management of other toxicities (eg, hepatotoxicity, infections, neutropenia, skin- and nail-related AEs, oral toxicities) reported with one or more bispecific antibodies

    MODULE 5: Utility of Belantamab Mafodotin for R/R MM

    • Mechanism of action and structural components of the BCMA-directed antibody-drug conjugate belantamab mafodotin
    • Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM; rationale for the withdrawal of this agent
    • Key findings with belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone for patients who have received ≥1 prior line of therapy; OS advantage documented with the former combination
    • Ongoing FDA review of belantamab mafodotin-based combination strategies; potential clinical role for R/R MM

    MODULE 6: Tolerability Considerations with Belantamab Mafodotin

    • Pathophysiology and symptomatology of the ocular AEs observed with belantamab mafodotin; impact of dosing on frequency and severity of ocular AEs
    • Indications for and timing of ophthalmologic referral for patients about to receive belantamab mafodotin
    • Optimal approaches to the management of ocular toxicities with belantamab mafodotin
    • Spectrum, frequency, severity and management of other common and uncommon toxicities reported with belantamab mafodotin

    MODULE 7: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) for MM

    • Mechanism of action of the CELMoDs iberdomide and mezigdomide; similarities and differences between CELMoDs and standard immunomodulatory agents (IMiDs)
    • Published efficacy and safety findings with iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for pretreated MM
    • Rationale for the use of minimal residual disease (MRD) negativity as a clinical trial endpoint for MM; emerging Phase III data indicating an improvement in MRD negativity rates with iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM
    • Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs

    MODULE 8: Tolerability/Toxicity Considerations with CELMoDs for MM

    • Comparative tolerability profiles of iberdomide, mezigdomide and traditional IMiDs
    • Spectrum, frequency and severity of hematologic AEs observed with CELMoDs in published clinical studies
    • Incidence and time course of nonhematologic complications (eg, gastrointestinal toxicities, cutaneous AEs, fatigue, infections, peripheral neuropathy) reported with CELMoDs
    • Toxicity and tolerability of iberdomide and mezigdomide in combination with other effective antimyeloma therapies; strategies to discern the effects of each individual agent
    • Appropriate monitoring, mitigation and management protocols for hematologic and nonhematologic side effects with CELMoDs

    Target Audience
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

    Learning Objectives
    Upon completion of this activity, participants should be able to

    • Consider published research findings and other clinical factors that affect the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
    • Evaluate the biological rationale for chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and discuss with patients when and if this novel strategy should be considered.
    • Educate patients with R/R MM about the mechanism of action of, available data with and current clinical role of BCMA- and non-BCMA-directed bispecific antibodies.
    • Review recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential clinical role of this form of treatment.
    • Appreciate the mechanism of action of, unique characteristics of and available and emerging data with the various cereblon E3 ligase modulators under development, to prepare for their potential clinical availability for patients with R/R MM.
    • Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used, recently approved and promising emerging systemic therapies for MM.

    Accreditation Statement
    Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    Credit Designation Statements
    This educational activity for 1.5 contact hours is provided by Research To Practice.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/RRMultipleMyeloma/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    Credit Form
    To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

    Privacy Policy
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    Unlabeled/Unapproved Uses Notice
    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

    Content Validation and Disclosures
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Dr Faiman — Advisory Committees and Consulting Agreements: Janssen Biotech Inc, Sanofi. Dr Lee — Consulting Agreements (Paid to Institution): AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements (Paid to Self): Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc. Dr Steinbach — Advisory Committees: Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research and Speakers Bureaus: Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc.

    MODERATOR — Dr Callander has no relevant financial relationships to disclose.

    RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
    Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    Supporters
    This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

    Location
    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, TX 78205
    Hotel Phone: (210) 223-1000

    Meeting Room
    Grand Ballroom A-F (Third Floor)

    Directions
    The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

     

    Registration is now closed.

    Inside the Issue: The Emerging Role of Cereblon E3 Ligase Modulators in Multiple Myeloma

    Accreditation types: 1.25 ABIM MOC, CME

    Expires: February 2027

    To play this presentation please log in.

    Don't have an account?

    Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

    Faculty

    Natalie S Callander

    Faculty

    Natalie S Callander

    MD

    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

    Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

    Paul G Richardson

    Faculty

    Paul G Richardson

    MD

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center

    Harvard Medical School, Boston, Massachusetts

    RJ Corman Professor of Medicine

    TARGET AUDIENCE
    This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

    LEARNING OBJECTIVES

    • Describe cereblon’s function in multiple myeloma (MM) formation and growth and its role in the degradation of key oncogenic proteins in order to better understand the rationale for the development of cereblon E3 ligase modulators (CELMoDs).
    • Review the mechanism of action and unique characteristics of the CELMoDs under development for MM, and appreciate the similarities and differences between these therapies and currently approved immunomodulatory agents.
    • Evaluate published efficacy and safety findings with CELMoDs in the advanced stages of development to prepare for the potential clinical availability of these agents for patients with relapsed/refractory (R/R) MM.
    • Assess the biological rationale for combining CELMoDs with other agents commonly administered to patients with MM, and recognize available and emerging research findings with various combination approaches.
    • Appreciate the frequency and severity of various therapy-related adverse events encountered by patients undergoing treatment with CELMoDs, and use this knowledge to identify, manage and mitigate resultant side effects.
    • Consider the rationale for and designs of ongoing clinical trials evaluating CELMoDs for newly diagnosed and R/R MM, and counsel appropriately selected patients about the potential benefits of study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CE ACTIVITY
    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/InsideTheIssue2025/CELMoDsMM/Video/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Natalie S Callander, MD
    Professor of Medicine
    Director, Myeloma Clinical and Cellular Therapy Program
    University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin

    No relevant financial relationships to disclose.

    Paul G Richardson, MD
    Clinical Program Leader and Director of Clinical Research
    Jerome Lipper Multiple Myeloma Center
    Dana-Farber Cancer Institute
    RJ Corman Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Oncopeptides.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    These activities are supported by an educational grant from Bristol Myers Squibb. 

    Release date: February 2026
    Expiration date: February 2027

    After completing the post-test, learners may download and review the answers here to identify further areas for study.

    Byun JM et al. Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1. ASH 2025;Abstract 5835.

    Hartley-Brown MA et al. Mezigdomide-A novel cereblon E3 ligase modulator under investigation in relapsed/refractory multiple myeloma. Cancers (Basel) 2024 Mar 15;16(6):1166. Abstract

    Korst CLBM et al. Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): A multicentre, single arm, phase 2 trial. Lancet Haematol 2026;13(1):e30-40. Abstract

    Landgren O et al. A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The ReKinDLE study. ASH 2025;Abstract 251.

    Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract

    Merz L et al. The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial. ASH 2025;Abstract 1033.

    Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: STOMP phase 1 results. ASH 2025;Abstract 4010.

    Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070.

    Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372.

    Richardson PG et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial. ASH 2023;Abstract 1013.

    Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract

    Richardson PG et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132-47. Abstract

    Suvannasankha A et al. Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial. ASH 2025;Abstract 100.

    van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101.

    van de Donk NWCJ et al. The role of CELMoD agents in multiple myeloma. Onco Targets Ther 2025;18:921-33. Abstract

    White D et al. Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial. ASCO 2025;Abstract 7532.

    • Inside the Issue
    • multiple myeloma

    Discussing Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma

    Accreditation types: 1.25 ABIM MOC, ABS MOC, CME

    Expired: August 2026

    To play this presentation please log in.

    Don't have an account?

    Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

    Faculty

    Natalie S Callander

    Natalie S Callander

    MD

    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

    Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

    Sagar Lonial

    Sagar Lonial

    MD, FACP, FASCO

    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

    Chair and Professor, Department of Hematology and Medical Oncology, Chief Medical Officer

    TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma.

    LEARNING OBJECTIVES

    • Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
    • Understand the mechanisms of action of and pivotal clinical trial findings with FDA-approved novel therapies to facilitate their integration into MM management algorithms.
    • Evaluate the biological rationale for exploiting B-cell maturation antigen (BCMA) in the management of MM, and understand the similarities and differences among available and investigational therapies directed at this target.
    • Assess available findings with BCMA-directed chimeric antigen receptor T-cell therapy and bispecific antibodies for MM, and recognize patients for whom treatment with one of these novel agents would be appropriate.
    • Review recently presented research establishing the efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential clinical role of this form of treatment.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue.

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS ACTIVITY

    CME credit is no longer available for this issue.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Natalie S Callander, MD
    Director, Myeloma Clinical Program
    University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin

    No relevant financial relationships to disclose.

    Sagar Lonial, MD, FACP
    Chair and Professor
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Boards of Directors: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: TG Therapeutics Inc.

    SURVEY PARTICIPANTS — Rafael Fonseca, MD — Boards of Directors: Antengene; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc, Apple, Bristol Myers Squibb, Celgene Corporation, GSK, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc, RA Capital Management, Regeneron Pharmaceuticals Inc, Sanofi; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb; Patents (Through Institution): Abbott; Scientific Advisory Boards: Caris Life Sciences; Stock Options/Stock — Public Companies: Antengene, Caris Life Sciences. Robert Z Orlowski, MD, PhD — Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, CellCentric, DEM BioPharma, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neoleukin Therapeutics Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Stock Options — Private Companies: Asylia Therapeutics Inc. Noopur Raje, MD — Advisory Committees: Advisor to AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Johnson & Johnson, Pfizer Inc, Sanofi. Paul G Richardson, MD — Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Oncopeptides.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    These activities are supported by an educational grant from GSK.

    Release date: August 2025
    Expiration date: August 2026

    Bahlis NJ et al. Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial. Nat Med 2023;29(10):2570-6. Abstract

    Beksac M et al. Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf). ASCO 2025;Abstract 7544.

    Chari A et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387(24):2232-44. Abstract

    Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;391:408-21. Abstract

    Dimopoulos MA et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma. EHA 2024;Abstract LB3440.

    Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024;391(5):393-407. Abstract

    Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.

    Hungria VTM et al. Characterization and management of ocular events in patients (Pts) treated with belantamab mafodotin (Belamaf) plus bortezomib and dexamethasone (BVd) in the DREAMM-7 study. IMS 2024;Abstract P-396.

    Jain MD. Prolonged neurologic symptoms after CAR T cell therapy — What is it? Transplant Cell Ther 2025;31(4):190-1. Abstract

    Kowalski A et al. Tocilizumab prophylaxis for patients with relapsed or refractory multiple myeloma treated with teclistamab, elranatamab or talquetamab. ASH 2024;Abstract 932.

    Lin Y et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. ASCO 2023;Abstract 8009.

    Mateos M-V et al. Results from DREAMM-7 a randomized phase 3 study of belantamab mafodotin + bortezomib, and dexamethasone vs daratumumab + bortezomib, and dexamethasone in relapsed/refractory multiple myeloma. EHA 2024;Abstract S214.

    Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387(6):495-505. Abstract

    Nooka AK et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. ASCO 2023;Abstract 8008.

    Quach H et al. Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study. IMS 2024;Abstract P-413.

    Rodriguez-Ortero P et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388(11):1002-14. Abstract

    San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389(4):335-47. Abstract

    Sidana S et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood 2025;145(1):85-97. Abstract

    Tan CR et al. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study. Blood Cancer J 2025;15(1):53. Abstract

    Terpos E et al. Practical guidance on clinical management of belantamab mafodotin-associated ocular events. Am J Hematol 2025;[Online ahead of print]. Abstract

    Tomasson M et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM). ASH 2023;Abstract 3385.

    Trudel S et al. Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial. ASCO 2025;Abstract 7515.

    Trudel S et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2024;Abstract LBA105.

    Velasco R et al. CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern? Front Neurol 2023;14. Abstract

    Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma

    To play this presentation please log in.

    Don't have an account?

    Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

    Faculty

    Natalie S Callander

    Natalie S Callander

    MD

    University of Wisconsin Carbone Cancer Center Madison, Wisconsin

    Professor of Medicine Director, Myeloma Clinical and Cellular Therapy Program

    Sagar Lonial

    Sagar Lonial

    MD, FACP, FASCO

    Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia

    Chair and Professor Department of Hematology and Medical Oncology Chief Medical Officer

    TARGET AUDIENCE
    This special webinar is designed to educate patients about relapsed/refractory multiple myeloma. Participants will learn about what is important in a diagnosis, what treatment options are available and what side effects may be encountered.

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS ACTIVITY
    This activity consists of a video component. The participant may review the faculty information and watch the video located at ResearchToPractice.com/PatientProject2024/RRMMPatients/Video.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Natalie S Callander, MD
    Director, Myeloma Clinical Program
    University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin

    No relevant financial relationships to disclose.

    Sagar Lonial, MD, FACP
    Chair and Professor
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Boards of Directors: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: TG Therapeutics Inc.

    SURVEY PARTICIPANTS — Rafael Fonseca, MD — Boards of Directors: Antengene; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc, Apple, Bristol Myers Squibb, Celgene Corporation, GSK, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc, RA Capital Management, Regeneron Pharmaceuticals Inc, Sanofi; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb; Patents (Through Institution): Abbott; Scientific Advisory Boards: Caris Life Sciences; Stock Options/Stock — Public Companies: Antengene, Caris Life Sciences. Robert Z Orlowski, MD, PhD — Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, CellCentric, DEM BioPharma, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neoleukin Therapeutics Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Stock Options — Private Companies: Asylia Therapeutics Inc. Noopur Raje, MD — Advisory Committees: Advisor to AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Johnson & Johnson, Pfizer Inc, Sanofi. Paul G Richardson, MD — Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Oncopeptides. Paul G Richardson, MD — Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Oncopeptides.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    These activities are supported by an educational grant from GSK.